Halberd to Conduct Animal Tests of Nasal Spray that Blocks Negative Effects of Head Trauma

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) announced animal testing of its patent-pending nasal spray at Mississippi State University to address the effects of Traumatic Brain Injury (TBI). This research follows successful in vitro results in collaboration with Youngstown State University and aims to mitigate TBI-related neurological complications such as PTSD. The triple-action nasal spray can be administered promptly post-injury to potentially reduce long-term damage. Funding for the animal testing program has been secured, with Dr. Russell Carr overseeing the research.

Positive

• Successfully advanced to in vivo animal testing after in vitro studies.
• Secured funding for the testing program at Mississippi State University.
• Potential to significantly benefit military personnel and athletes by addressing TBI-related complications.

Negative

• None.

Tests to be scheduled at Mississippi State University

JACKSON CENTER, PA / ACCESSWIRE / January 31, 2023 / Halberd Corporation (OTC PINK:HALB) confirmed that animal testing at Mississippi State University (MSU) will focus on Halberd's patent-pending nasal spray to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining a head Injury. The work will be conducted over the next several months under the direction of Dr. Russell Carr, of the College of Veterinary Medicine.

Following Halberd's in vitro successful eradication of each known antigen associated with head trauma, including TBI, in collaboration with Youngstown State University, in vivo studies are to commence at Mississippi State University. Funding for the program has already been approved.

Head trauma initiates a cascade of overproduction of certain proteins and inflammatory cytokines in the brain. This overproduction, depending on the magnitude of the injury, often manifests itself in neurological changes in behavior, such as PTSD, aggression and suicide ideation. Halberd's triple-action nasal spray is designed to counteract these TBI-related complications by blocking the overproduction mechanism and allowing the brain to recover naturally. The benefits of such an approach in treating head injuries to military personnel, contact sports athletes and ordinary people who experience head trauma are monumental.

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "We have been very impressed by the protocol for testing traumatic brain injury in animals by the professors at Mississippi State University. What sets Halberd's nasal spray treatment apart is the ability to administer the treatment soon after injury in any setting, thus reducing the potential for serious permanent neurological damage."

William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "Selecting a source for animal testing of our anti-traumatic brain injury nasal spray was a very difficult process. Many universities we met with simply didn't have the process, experience, or expertise to conduct the tests in a manner that would yield our desired results. Mississippi State University has developed the procedures and delivered a test protocol that meets Halberd's rigid specifications. We look forward to a successful program with Mississippi State University."

To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/737355/Halberd-to-Conduct-Animal-Tests-of-Nasal-Spray-that-Blocks-Negative-Effects-of-Head-Trauma

FAQ

What is Halberd Corporation's latest announcement regarding its nasal spray?

Halberd Corporation announced that it will conduct animal tests on its nasal spray for treating Traumatic Brain Injury at Mississippi State University.

When will the animal testing for Halberd's nasal spray take place?

The animal testing is scheduled to commence over the next several months.

What are the expected benefits of Halberd's nasal spray for Traumatic Brain Injury?

The nasal spray aims to mitigate TBI-related complications like PTSD and reduce the likelihood of permanent neurological damage.

What is the significance of the animal testing being conducted at Mississippi State University?

Mississippi State University has developed a testing protocol that meets Halberd's specifications, ensuring rigorous evaluation of the nasal spray's effectiveness.

What stage is Halberd Corporation at in its nasal spray development?

Halberd has successfully completed in vitro studies and is now moving to in vivo animal testing.